Compugen 미래 성장

Future 기준 확인 0/6

Compugen 의 수익은 연간 59.8% 감소할 것으로 예상되는 반면, 연간 수익은 2.3% 로 증가할 것으로 예상됩니다. 2.3% 연간. EPS는 연간 59.1% 만큼 쇠퇴할 것으로 예상됩니다.

주요 정보

-59.8%

수익 성장률

-59.1%

EPS 성장률

Biotechs 수익 성장	27.6%
매출 성장률	2.3%
향후 자기자본 수익률	n/a
애널리스트 커버리지	Low
마지막 업데이트	13 Nov 2024

최근 미래 성장 업데이트

Analysts Have Been Trimming Their Compugen Ltd. (NASDAQ:CGEN) Price Target After Its Latest Report

May 22

Recent updates

Investors Aren't Buying Compugen Ltd.'s (NASDAQ:CGEN) Revenues

Aug 22

Analysts Have Been Trimming Their Compugen Ltd. (NASDAQ:CGEN) Price Target After Its Latest Report

May 22

Why Investors Shouldn't Be Surprised By Compugen Ltd.'s (NASDAQ:CGEN) 25% Share Price Plunge

May 01

Is Compugen Ltd. (NASDAQ:CGEN) Trading At A 36% Discount?

Apr 05

Compugen Ltd.'s (NASDAQ:CGEN) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Mar 08

Here's Why We're Not Too Worried About Compugen's (NASDAQ:CGEN) Cash Burn Situation

Mar 04

Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth

Sep 21

Compugen appoints Alberto Sessa as CFO

Sep 12

Compugen gets Japanese patent for COM701, anti-PVRIG antibodies

Aug 24

Compugen Q2 2022 Earnings Preview

Aug 03

Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth

Jun 23

Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth

Mar 02

Here's Why We're Not Too Worried About Compugen's (NASDAQ:CGEN) Cash Burn Situation

Nov 04

Shareholders Will Probably Not Have Any Issues With Compugen Ltd.'s (NASDAQ:CGEN) CEO Compensation

Aug 27

Companies Like Compugen (NASDAQ:CGEN) Can Afford To Invest In Growth

Jun 28

Compugen gains on takeover speculation after iTeos Therapeutics deal

Jun 14

Compugen reports updated COM701 data from Phase 1 study at ASCO21

Jun 08

Compugen's COM902 demonstrates potential benefit in cancer

Apr 27

Here's Why We're Not At All Concerned With Compugen's (NASDAQ:CGEN) Cash Burn Situation

Mar 15

Are Institutions Heavily Invested In Compugen Ltd.'s (NASDAQ:CGEN) Shares?

Feb 08

A Look At The Fair Value Of Compugen Ltd. (NASDAQ:CGEN)

Jan 04

Compugen earns $2M milestone under antibody development deal with AstraZeneca

Dec 23

Here's Why We're Not At All Concerned With Compugen's (NASDAQ:CGEN) Cash Burn Situation

Nov 30

Compugen Ltd. 2020 Q3 - Results - Earnings Call Presentation

Nov 08

수익 및 매출 성장 예측

NasdaqCM:CGEN - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	47	-6	7	N/A	2
12/31/2025	40	-6	-10	N/A	2
12/31/2024	51	3	97	N/A	2
9/30/2024	60	2	N/A	N/A	N/A
6/30/2024	43	-10	22	22	N/A
3/31/2024	36	-17	N/A	N/A	N/A
12/31/2023	33	-19	-36	-36	N/A
9/30/2023	8	-32	N/A	N/A	N/A
6/30/2023	8	-33	-32	-32	N/A
3/31/2023	8	-33	N/A	N/A	N/A
12/31/2022	8	-34	-35	-34	N/A
9/30/2022	N/A	-39	N/A	N/A	N/A
6/30/2022	6	-34	-30	-30	N/A
3/31/2022	6	-34	N/A	N/A	N/A
12/31/2021	6	-34	-23	-23	N/A
9/30/2021	8	-34	N/A	N/A	N/A
6/30/2021	2	-36	-31	-30	N/A
3/31/2021	2	-32	N/A	N/A	N/A
12/31/2020	2	-30	-28	-28	N/A
9/30/2020	N/A	-28	N/A	N/A	N/A
6/30/2020	N/A	-26	-23	-23	N/A
3/31/2020	N/A	-26	N/A	N/A	N/A
12/31/2019	N/A	-27	-28	-28	N/A
9/30/2019	N/A	-30	N/A	N/A	N/A
6/30/2019	8	-27	-22	-22	N/A
3/31/2019	8	-31	N/A	N/A	N/A
12/31/2018	18	-23	-13	-13	N/A
9/30/2018	18	-23	N/A	N/A	N/A
6/30/2018	10	-29	N/A	-23	N/A
3/31/2018	10	-28	N/A	N/A	N/A
12/31/2017	N/A	-37	N/A	-31	N/A
9/30/2017	0	-36	N/A	N/A	N/A
6/30/2017	0	-34	N/A	-27	N/A
3/31/2017	1	-32	N/A	N/A	N/A
12/31/2016	1	-32	N/A	-20	N/A
9/30/2016	9	-23	N/A	N/A	N/A
6/30/2016	9	-22	N/A	-20	N/A
3/31/2016	9	-23	N/A	N/A	N/A
12/31/2015	9	-20	N/A	-26	N/A
9/30/2015	8	-21	N/A	N/A	N/A
6/30/2015	9	-20	N/A	-17	N/A
3/31/2015	11	-15	N/A	N/A	N/A
12/31/2014	12	-11	N/A	-11	N/A
9/30/2014	8	-13	N/A	N/A	N/A
6/30/2014	7	-12	N/A	-7	N/A
3/31/2014	6	-13	N/A	N/A	N/A
12/31/2013	4	-14	N/A	-6	N/A

애널리스트 미래 성장 예측

수입 대 저축률: CGEN 의 수익은 향후 3년간 감소할 것으로 예상됩니다(연간 -59.8% ).

수익 vs 시장: CGEN 의 수익은 향후 3년간 감소할 것으로 예상됩니다(연간 -59.8% ).

고성장 수익: CGEN 의 수익은 향후 3년간 감소할 것으로 예상됩니다.

수익 대 시장: CGEN 의 수익(연간 2.3% ) US 시장( 9.2% 보다 느리게 성장할 것으로 예상됩니다. 9.2% 연간).

고성장 수익: CGEN 의 수익(연간 2.3% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: CGEN 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

성장 기업 발견

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2024/12/26 09:50
장 마감 주가	2024/12/26 00:00
수익	2024/09/30
연간 수익	2023/12/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.

애널리스트 출처

Compugen Ltd. 10 애널리스트 중 2 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Varun Kumar	Cantor Fitzgerald & Co.
Ling Wang	Chardan Capital Markets, LLC
Vernon Bernardino	FBR Capital Markets & Co.

Compugen 미래 성장

Future 기준 확인 0/6

주요 정보

최근 미래 성장 업데이트

Forecast to breakeven in 2024

Price target decreased by 25% to US$4.00

Forecast to breakeven in 2025

Analysts Have Been Trimming Their Compugen Ltd. (NASDAQ:CGEN) Price Target After Its Latest Report

Consensus revenue estimates increase by 41%, EPS downgraded

Consensus revenue estimates fall by 45%

Recent updates

Compugen Ltd. Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG Antibodies

Forecast to breakeven in 2024

Compugen Ltd. to Present Anti-Tumor Activity and Safety Data of COM701, COM902 and Pembrolizumab Combination in Patients with Platinum Resistant Ovarian Cancer at SITC 2024

Compugen Ltd. to Report Q3, 2024 Results on Nov 12, 2024

Price target decreased by 25% to US$4.00

Investors Aren't Buying Compugen Ltd.'s (NASDAQ:CGEN) Revenues

New minor risk - Profitability

New major risk - Revenue and earnings growth

Forecast to breakeven in 2025

Compugen Ltd., Annual General Meeting, Sep 12, 2024

Compugen Ltd. Announces FDA Clearance of IND for Com503 for the Treatment of Solid Tumors

Compugen Ltd. to Report Q2, 2024 Results on Aug 06, 2024

Analysts Have Been Trimming Their Compugen Ltd. (NASDAQ:CGEN) Price Target After Its Latest Report

Compugen Ltd. Announces CFO Changes, Effective August 15, 2024

Compugen Ltd. to Report Q1, 2024 Results on May 20, 2024

Why Investors Shouldn't Be Surprised By Compugen Ltd.'s (NASDAQ:CGEN) 25% Share Price Plunge

Is Compugen Ltd. (NASDAQ:CGEN) Trading At A 36% Discount?

New minor risk - Shareholder dilution

Consensus revenue estimates increase by 41%, EPS downgraded

Now 23% undervalued

New major risk - Revenue and earnings growth

Compugen Ltd.'s (NASDAQ:CGEN) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Compugen Ltd. to Report Q4, 2023 Results on Mar 05, 2024

Compugen (NASDAQ:CGEN) Is In A Good Position To Deliver On Growth Plans

Compugen Ltd. Announces Executive Changes

New major risk - Revenue and earnings growth

Consensus revenue estimates fall by 45%

Compugen Announces Receipt of Nasdaq Minimum Bid Price Notification

Compugen Ltd. Announces to Present New Data At Sitc 2023 Suggesting Leading Edge of Anti-Il18 Binding Protein Antibody, Com503, in Treating Cancer

Compugen Ltd. to Report Q3, 2023 Results on Nov 07, 2023

Will Compugen (NASDAQ:CGEN) Spend Its Cash Wisely?

Insufficient new directors

New major risk - Revenue and earnings growth

Consensus EPS estimates upgraded to US$0.31 loss

Compugen Ltd., Annual General Meeting, Sep 20, 2023

Compugen Ltd. to Report Q2, 2023 Results on Aug 07, 2023

Price target decreased by 7.0% to US$5.50

Compugen Ltd. Doses First Patient in Triple Immunotherapy Combination COM701, COM902 and Pembrolizumab Platinum Resistant Ovarian Cancer Proof-Of-Concept Study

Is Compugen (NASDAQ:CGEN) In A Good Position To Invest In Growth?

Compugen Regains Compliance with Nasdaq Minimum Bid Price Requirement

Price target increased by 15% to US$6.80

Here's Why We're Not Too Worried About Compugen's (NASDAQ:CGEN) Cash Burn Situation

Compugen Ltd. to Report Q4, 2022 Results on Feb 27, 2023

Compugen Ltd.'s COM701 (anti-PVRIG) in Dual and Triple Combination Demonstrates Preliminary Durable Anti-Tumor Activity and Immune Activation in Patients with Platinum Resistant Ovarian Cancer

Price target decreased to US$6.29

Compugen Demonstrates Preliminary Anti-Tumor Activity and Potent Immune Activation in Metastatic MSS-CRC Patients

Compugen Announces Receipt of Nasdaq Delisting Notice

Compugen Ltd. to Report Q3, 2022 Results on Nov 14, 2022

Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth

Compugen Ltd. Announces Appointment of Alberto Sessa as Chief Financial Officer

Compugen appoints Alberto Sessa as CFO

Compugen gets Japanese patent for COM701, anti-PVRIG antibodies

Compugen Ltd. Announces Resignation of Ari Krashin as Chief Operating Officer in August 2022

Compugen Q2 2022 Earnings Preview

Compugen Ltd. to Report Q2, 2022 Results on Aug 04, 2022

Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth

Compugen Announces CFO Departure

Compugen Ltd. to Report Q1, 2022 Results on May 16, 2022

Price target decreased to US$14.00

Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth

Compugen Ltd. Announces Board Changes

Compugen Ltd. to Report Q4, 2021 Results on Feb 24, 2022

Price target decreased to US$18.57

Compugen Expands COM701 Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use with anti-PD-1 and anti-TIGIT Antibodies

Here's Why We're Not Too Worried About Compugen's (NASDAQ:CGEN) Cash Burn Situation

Shareholders Will Probably Not Have Any Issues With Compugen Ltd.'s (NASDAQ:CGEN) CEO Compensation

Compugen Announces Bispecific Antibody Derived from COM902 to Enter Clinical Development

High number of new directors

Compugen Doses First Patient in Phase 1/2 Triple Combination Cohort Expansion of COM701 with Opdivo® and Bristol Myers Squibb's Anti-TIGIT Antibody, BMS-986207